176 related articles for article (PubMed ID: 21593191)
1. CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability.
Wang H; Zhang C; Rorick A; Wu D; Chiu M; Thomas-Ahner J; Chen Z; Chen H; Clinton SK; Chan KK; Wang Q
Cancer Res; 2011 Jul; 71(14):4866-76. PubMed ID: 21593191
[TBL] [Abstract][Full Text] [Related]
2. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth.
Chen Z; Zhang C; Wu D; Chen H; Rorick A; Zhang X; Wang Q
EMBO J; 2011 May; 30(12):2405-19. PubMed ID: 21556051
[TBL] [Abstract][Full Text] [Related]
3. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
4. MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand.
Liu G; Sprenger C; Wu PJ; Sun S; Uo T; Haugk K; Epilepsia KS; Plymate S
Oncotarget; 2015 Jan; 6(1):288-304. PubMed ID: 25481872
[TBL] [Abstract][Full Text] [Related]
5. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
[TBL] [Abstract][Full Text] [Related]
6. Anticancer effect of icaritin on prostate cancer via regulating miR-381-3p and its target gene UBE2C.
Hu J; Wu X; Yang C; Rashid K; Ma C; Hu M; Ding Q; Jiang H
Cancer Med; 2019 Dec; 8(18):7833-7845. PubMed ID: 31646760
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.
Zhang Y; Castaneda S; Dumble M; Wang M; Mileski M; Qu Z; Kim S; Shi V; Kraft P; Gao Y; Pak J; Sapra P; Bandaru R; Zhao H; Vessella RL; Horak ID; Greenberger LM
Mol Cancer Ther; 2011 Dec; 10(12):2309-19. PubMed ID: 22027692
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma.
Bavi P; Uddin S; Ahmed M; Jehan Z; Bu R; Abubaker J; Sultana M; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Prabhakaran S; Hussain AR; Al-Kuraya KS
Am J Pathol; 2011 May; 178(5):2109-20. PubMed ID: 21514426
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Gan L; Chen S; Wang Y; Watahiki A; Bohrer L; Sun Z; Wang Y; Huang H
Cancer Res; 2009 Nov; 69(21):8386-94. PubMed ID: 19826044
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker.
Xie C; Powell C; Yao M; Wu J; Dong Q
Int J Biochem Cell Biol; 2014 Feb; 47():113-7. PubMed ID: 24361302
[TBL] [Abstract][Full Text] [Related]
11. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
[TBL] [Abstract][Full Text] [Related]
12. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
[No Abstract] [Full Text] [Related]
13. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
[TBL] [Abstract][Full Text] [Related]
14. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
15. Involvement of ubiquitin-conjugating enzyme E2C in proliferation and invasion of prostate carcinoma cells.
Shuliang S; Lei C; Guangwu J; Changjie L
Oncol Res; 2013; 21(3):121-7. PubMed ID: 24512726
[TBL] [Abstract][Full Text] [Related]
16. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
[TBL] [Abstract][Full Text] [Related]
17. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Wu L; Birle DC; Tannock IF
Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
[TBL] [Abstract][Full Text] [Related]
18. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
[TBL] [Abstract][Full Text] [Related]
19. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
20. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma.
Lin J; Raoof DA; Wang Z; Lin MY; Thomas DG; Greenson JK; Giordano TJ; Orringer MB; Chang AC; Beer DG; Lin L
Neoplasia; 2006 Dec; 8(12):1062-71. PubMed ID: 17217624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
